Novo Nordisk seeks injunction to block Eli Lilly ads

Novo Nordisk is pursuing a preliminary U.S. court injunction to immediately block advertisements for Eli Lilly obesity and diabetes drugs. The lawsuit alleges that Lilly used outdated studies to create a false impression of superiority over Wegovy and Ozempic treatments.

Jul 24, 2026

X24 PerspectiveX24 Perspective